will resume in full with the edition of18 August 2018,
will resume in full with the edition of18 August 2018,
.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to email@example.com.
– pdf version: A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_28 Jul 2018
– blog edition: comprised of the approx. 35+ entries posted below.
– Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
– Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.
David R. Curry, MS
Center for Vaccine Ethics and Policy
To Our Readers: Vaccines and Global Health: The Week in Review will resume publication on 18 August 2018 following the Editor’s annual leave.
Milestones :: Perspectives
Ebola – DRC
Ebola outbreak in DRC ends: WHO calls for international efforts to stop other deadly outbreaks in the country
24 July 2018
News Release – KINSHASA/GENEVA
Today marks the end of the ninth outbreak of Ebola in the Democratic Republic of the Congo (DRC). The World Health Organization (WHO) congratulates the country and all those involved in ending the outbreak, while urging them to extend this success to combatting other diseases in DRC.
WHO Director-General, Dr Tedros Adhanom Ghebreyesus, and Regional Director for Africa, Dr Matshidiso Moeti, joined Minister of Health Dr Oly Ilunga for the announcement in Kinshasa.
“The outbreak was contained due to the tireless efforts of local teams, the support of partners, the generosity of donors, and the effective leadership of the Ministry of Health. That kind of leadership, allied with strong collaboration between partners, saves lives,” said Dr Tedros.
Unlike previous Ebola outbreaks in the country, this one involved four separate locations, including an urban centre with river connections to the capital and to neighbouring countries, as well as remote rainforest villages. There were initial concerns that the disease could spread to other parts of DRC, and to neighbouring countries.
Within hours of the outbreak being declared on 8 May, WHO released US$2 million from its Contingency Fund for Emergencies, deployed a team to augment capacity in the field, and activated an emergency incident management system.
“WHO moved quickly and efficiently,” said Dr Moeti, “We also demonstrated the tremendous capacity of the African region. More than three-quarters of the 360 people deployed to respond came from within the region. Dozens of experts from Guinea spent weeks leading Ebola vaccination efforts here, transferring expertise which will enable the DRC to mount an effective response both within its borders and beyond.”
Dr Tedros urged the DRC Government and the international community to build on the positive momentum generated by the quick containment of the Ebola outbreak.
“This effective response to Ebola should make the Government and partners confident that other major outbreaks affecting the country such as cholera and polio can also be tackled,” said Dr Tedros. “We must continue to work together, investing in strengthened preparedness and access to healthcare for the most vulnerable.”
:: WHO’s rapid response and scale up of operations in the DRC was funded by a total of US$4 million disbursement from the WHO Contingency Fund for Emergencies (CFE).
:: WHO and partners appealed for US$57 million to stop the spread of Ebola. The total funds received by all partners, as tracked by OCHA, amount to US$63 million.
:: Funding towards WHO’s contribution to the Ebola response was provided from: Italy (€ 300 000), UN CERF (US$ 800 000), Gavi (US$ 1 million), USAID (US$ 5.3 million), Wellcome Trust and UK-DFID (US$ 4.1 million), UK-DFID (£5 million), Germany (€5 million), Norway (NOK 8 million), Canada (CAD$1 million), World Bank PEF (US$ 6.8 million), Japan (US$1.3 million), EU ECHO (€ 1.5 million) and from the Ebola MPTF (US$ 428,000) bringing the total to approximately US$ 36 million.
:: Germany’s contribution is in recognition of the critical role the WHO CFE has played in responding to the Ebola virus disease outbreak in the Democratic Republic of the Congo and will go to replenish the CFE, which provided initial funds for the response efforts.
:: In-kind contributions for medical evacuation were received from Norway. EU ECHO support was provided for flights between Kinshasa and Mbandaka. Technical expertise was provided by Guinea, the UK, USA and Germany through the Global Outbreak Alert and Response Network (GOARN). Merck provided the vaccines that were used to protect over 3300 people.
WHO partners in the DRC Ebola response included the following:
The Alliance for International Medical Action (ALIMA), the International Federation of Red Cross and Red Crescent Societies (IFRC), the Red Cross of the Democratic Republic of the Congo (DR Congo Red Cross), Médecins Sans Frontières (MSF), the Disaster Relief Emergency Fund (DREF), the Africa Centers for Disease Control and Prevention (Africa-CDC), the US Centers for Disease Control and Prevention (US-CDC), ECHO, the Department for International Development (DFID), Japan International Cooperation Agency (JICA), the World Food Programme (WFP), UNICEF, UNCERF, UNOCHA, MONUSCO, UNFPA, International Organization for Migration (IOM), the FAO Emergency Management Centre – Animal Health (EMC-AH), the International Humanitarian Partnership (IHP), Gavi, the Vaccine Alliance, the African Field Epidemiology Network (AFENET), the UK Public Health Rapid Support team, the EPIET Alumni Network (EAN), the International Organisation for Animal Health (OIE), the Emerging Diseases Clinical Assessment and Response Network (EDCARN), the World Bank and PATH. The Government of Guinea deployed more than 30 Ministry of Health staff to assist with the ring vaccination campaign, and Merck provided the Ebola vaccine. Additional coordination and technical support through the Global Outbreak Alert and Response Network (GOARN), Association pour le développement de l’épidémiologie de terrain (EPITER), European Mobile Laboratory (EMLab), Infection Control Africa Network (ICAN), Institut Pasteur (IP), National Institute for Communicable Diseases (NICD), South Africa, Robert Koch Institut (RKI), and Emergency Medical Teams (EMT).
25 July 2018
Ebola vaccine praised as Congo outbreak declared over
DRC government officially declares end of outbreak following the vaccination of over 3,000 people.
Geneva, 25 July 2018 – The first use of a vaccine to help contain an Ebola outbreak has been encouraging, Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, said as the outbreak in the Democratic Republic of Congo (DRC) was officially declared over.
The DRC government formally declared the Ebola outbreak over on Tuesday 24 July after no new cases were reported for 42 days. From the 4 April through 9 July there were 54 confirmed cases of Ebola reported, with 33 deaths. A total of 3,300 people received investigational doses of the vaccine as part of a ring vaccination protocol – the same used to eradicate smallpox.
The vaccination was implemented by the Government of DRC and partners including WHO, which supported national authorities in coordinating the international health response, and Medecins Sans Frontieres (MSF). Gavi provided $1 million towards the vaccination effort.
“As soon as Ebola moved from isolated rural areas into Mbandaka – a major town and regional hub – there was justified concern that this outbreak could spiral out of control,” said Dr Berkley. “It took months of hard work by a global coalition of UN agencies, NGOs and governments, led by the DRC government with WHO support, to carry out the surveillance, containment, contact tracing and public education needed to contain and defeat Ebola. This was the first time a vaccine was used as part of this wider response and it is encouraging that there were no cases of Ebola among those given the vaccine. We also now have valuable experience of how this vaccine can be used effectively in the field.”
The vaccine has gone through Phase 3 trials, which showed the vaccine to be safe and highly effective, but has not yet been licensed by relevant regulatory authorities. While the vaccine goes through the licensing process, an agreement between Gavi and Merck, the developer of the Ebola vaccine, ensures that 300,000 investigational doses of the vaccine are available in case of an outbreak. It is these doses that were used in the DRC.
This agreement, an Advance Purchase Commitment announced in January 2016, is the first of its kind. It was designed to incentivise the rapid development of the vaccine as well as guarantee investigational doses are available while licensure is being secured. Gavi committed US$5 million to buy doses of a fully licensed vaccine as and when it becomes available. In return, Merck agreed to create the emergency stockpile…
Milestones :: Perspectives
New vaccination figures show millions more children being immunised in world’s poorest countries.
Geneva, 26 July 2018 – Children in fragile states are being left behind in the global effort to improve immunisation rates in the world’s poorest countries, an analysis by Gavi, the Vaccine Alliance of the latest global immunisation statistics has shown.
For the 68 developing countries in which Gavi works, the latest WHO/UNICEF Estimates of National Immunisation Coverage (WUENIC) show that coverage for the basic Diphtheria, Tetanus and Pertussis vaccine (DTP3) rose to 86% in 2017 from 80% in 2010, when fragile states are excluded.
However coverage has stagnated at 62% in fragile states. Five of the six Gavi-supported countries with less than 50% DTP3 coverage in 2017 were classed as fragile. The number of under-immunised children has also increased by 170,000 in Gavi-supported countries to 16.2 million children. Just under half of these children were in fragile countries.
In July 2017, Gavi introduced a new fragility, emergencies and refugee policy to boost the number of children receiving vaccines in fragile settings, especially among vulnerable populations. Bangladesh became the first country to take advantage of the policy in late 2017, carrying out Gavi-funded vaccination campaigns for Rohingya refugees in Cox’s Bazar.
“Over the last two decades we have made enormous progress in boosting vaccination coverage in many of the world’s poorest countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “Gavi is helping more children receive lifesaving vaccines than at any point in our history but millions of children are still being left behind, with half of these under-immunised children living in fragile countries. As an alliance we need to redouble our efforts and maintain our focus on routine immunisation as the most sustainable way to improve child health, strengthen health systems and boost economies.”..
Milestones :: Perspectives
China: “Vaccine Scandal”
See additional coverage in various publications in Media Watch below.
China vaccine scandal: investigations begin into faulty rabies and DTaP shots
BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3244 (Published 25 July 2018)
Trust in China’s authorities to guarantee the safety of medicines has been shaken after the nation’s second largest producer of rabies vaccines was found to have faked records.
Changsheng Biotechnology, based in the northeastern Jilin province, was ordered to cease producing a Vero cell based rabies vaccine on 15 July after China’s State Food and Drug Administration found that it had forged production and inspection data, the regulator said.1 Investigators reportedly acted on a tip-off from an ex-employee.
Changsheng issued an apology and announced a recall as shares in the company tumbled. It was not clear whether the batches had been released to market or how the substandard vaccine might affect people, but no injuries had been reported so far.
But days later Jilin’s provincial drug watchdog reported that the same company had last year sold over 250,000 faulty doses of a combined childhood shot for diphtheria, typhoid, and pertussis (DTaP), which it had uncovered in November. A local blogger apparently sent the story viral in a now deleted post that sparked confusion and anger among parents.
Local reports showed that police in Jilin swooped on the company on 23 July, arresting five executives including its chair, Gao Junfang, 64, who is also the company’s largest single shareholder. Gao and her family appeared on the Forbes 2016 rich list with combined assets of US$1bn (£0.76bn; €0.85bn).
China’s premier, Li Keqiang, said on 22 July that the incident had “crossed a moral line,” and he ordered an investigation. He was later joined by the president and Communist Party leader Xi Jinping, who called the scandal “vile in nature and shocking” and also ordered an investigation. Both urged severe punishment of those responsible.
At least four investigations are now under way, involving multiple regulators, police, securities inspectors, and the party’s feared anti-graft unit. Some people welcomed the strength of the response, in a nation where local reporting on such scandals has often been censored and whistleblowers jailed.
Others noted that it has been a decade since melamine laced powdered milk killed six babies and caused 54 000 others to be admitted for kidney damage, in a product safety case that still ripples today.2
In 2016 over 200 people were arrested over a different scandal involving expired and improperly refrigerated vaccines, which saw “middlemen” banned and provincial health bodies instructed to buy vaccines directly from manufacturers.
The Changsheng scandal is expected to trigger a renewed run on health services in Hong Kong, where parents were already travelling to secure vaccines for their children. One Hong Kong based biotech insider told The BMJ that his colleagues from the mainland were already “bringing their kids across the border for vaccinations.”
He said, “If you are in [neighbouring] Shenzhen you can bring your kids to Hong Kong, but I have no idea what parents in the interior of China are going to do. With the cold chain it’s much harder to get around than just importing tins of foreign powdered milk.”
The People’s Republic of China has the second highest number of reported rabies cases in the world, say data from the World Health Organization.3 But deaths from the disease more than halved from 2013 (1128 deaths) to 2017 (502) [WHO China, email communication]. Last year China reported no cases of diphtheria, 10 791 cases of typhoid (three fatal), and 10 390 cases of pertussis (none fatal), showed figures from China’s National Health Commission.4
 The person in charge of the State Food and Drug Administration introduced the Changchun Longevity Vaccine Case: ordered to suspend production, file an investigation, and organize flight inspections for all vaccine manufacturers. Xinhua News Agency 22 July 2018. http://samr.saic.gov.cn/xw/yw/zj/201807/t20180722_275178.html. [Translatable to English]
 Parry J. China’s tainted milk scandal spreads around world. BMJ2008;337:a1890. doi:10.1136/bmj.a1890 pmid:18829644
FullTextFREE Full TextGoogle Scholar
 World Health Organization Rabies. www.wpro.who.int/china/mediacentre/factsheets/rabies/en/.
 National Health and Family Planning Commission. Overview of the national legal infectious disease epidemic in 2017. 26 Feb 2018. www.nhfpc.gov.cn/jkj/s3578/201802/de926bdb046749abb7b0a8e23d929104.shtml. [Translatable to English]
Featured Journal Content
Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 14, Issue 7 2018
Evaluation of the impact of Shandong illegal vaccine sales incident on immunizations in China
Lei Cao, Jingshan Zheng, Lingsheng Cao, Jian Cui & Qiyou Xiao
Published online: 19 Jun 2018
A case of illegal vaccine sales in Shandong province, China, (hereinafter, the incident), which caused a lack of confidence among vaccination recipients and public panic, was uncovered in March 2016. We conducted a study comprising two cross-sectional surveys: at two months (May 2016) and seven months (October 2016) after the incident. The study aimed to evaluate the impact on immunizations; investigate the variation of the immunization coverage of the National Immunization Program Vaccines (NIPV) and the sales volume growth rate of Category II vaccines; and understand the reasons for non-vaccination and perspectives on immunization. The immunization coverage of NIPV decreased by 5.6 percentage points in the first survey, with a decline of 11.1 in the region of the incident, and decreased by 0.6 in the second survey compared to same period in 2015. The sales volume growth rate of Category II vaccines decreased by 25.8% in the study area and by 48.8% in the region of the incident in April 2016 compared to April 2015. Overall, 15.8% of respondents in the first survey and 7.0% in the second survey did not vaccinate their children according to the NIPV schedule because of the incident (X2=78.463, P<0.05). The vaccination was likely affected by the incident in varying degrees, especially in the involved region and particularly in relation to Category II vaccines. Overall, 34% of respondents avoided Category II vaccines for their children, indicating that it will take considerable time to eliminate the negative stigma associated with the incident.